AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35762237 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 exposure at 40,000 ppm (High: H)
Number of subjects: 12
Study 35762237 — intervention group
Group type: COMPARATOR
Intervention: Normal CO2 condition (C)
Number of subjects: 12
Study 34205461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 28
Study 36423412 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT)
Number of subjects: 103
Study 36423412 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered supportive therapy (ISUPPORT)
Number of subjects: 103
Study 36423412 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 103
Study 32037021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (12 sessions lasting 2 hours each, 3 follow-up monthly sessions, and 1 closing session)
Number of subjects: 171
Study 32037021 — intervention group
Group type: COMPARATOR
Intervention: Nonintensive control (3 sessions about healthy lifestyles lasting 1 hour each)
Number of subjects: 171
Study 35672921 — intervention group
Group type: EXPERIMENTAL
Intervention: One Drop digital health program
Number of subjects: 125
Study 35672921 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 32627049 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomedullary contrast-enhanced CT (CM-CECT)
Number of subjects: 177
Study 32627049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrographic contrast-enhanced CT (NG-CECT)
Number of subjects: 177
Study 32627049 — intervention group
Group type: COMPARATOR
Intervention: Combined data across all three phases
Number of subjects: 177
Study 32627049 — intervention group
Group type: COMPARATOR
Intervention: Machine learning models trained with one phase
Number of subjects: 177
Study 36308296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 563
Study 36308296 — intervention group
Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy
Number of subjects: 563
Study 33933474 — intervention group
Group type: COMPARATOR
Intervention: BEAM (carmustine, etoposide, cytarabine, melphalan)
Number of subjects: 101
Study 33933474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mx-Mel (mitoxantrone, melphalan)
Number of subjects: 101
Study 35948209 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly treatment with pegcetacoplan
Number of subjects: 156
Study 35948209 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-month (EOM) treatment with pegcetacoplan
Number of subjects: 156
Study 35948209 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 156
Study 33974324 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg intervention (1 egg per day)
Number of subjects: 660
Study 33974324 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 660
Study 36239660 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 111
Study 33721598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 118
Study 32316854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic potentiating (DYN)
Number of subjects: 40
Study 32316854 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study 36435822 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser correction technology
Number of subjects: 71
Study 36435822 — intervention group
Group type: COMPARATOR
Intervention: Traditional correction method
Number of subjects: 71
Study 33750594 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual counselor (VICKY)
Number of subjects: 273
Study 33750594 — intervention group
Group type: COMPARATOR
Intervention: My Family Health Portrait (MFHP)
Number of subjects: 273
Study 33078673 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 0
Study 34459496 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training combined with respiratory muscle training (W+RMT)
Number of subjects: 30
Study 34459496 — intervention group
Group type: COMPARATOR
Intervention: Respiratory muscle training (RMT)
Number of subjects: 30
Study 33610562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 gram)
Number of subjects: 26
Study 33610562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34308854 — intervention group
Group type: EXPERIMENTAL
Intervention: RA combined with CB
Number of subjects: 120
Study 34308854 — intervention group
Group type: COMPARATOR
Intervention: Semicompliant balloon (SB)
Number of subjects: 120
Study 32013958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine treatment for 4 weeks
Number of subjects: 154
Study 35224797 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP (4300 m)
Number of subjects: 9
Study 35224797 — intervention group
Group type: COMPARATOR
Intervention: NORM (1585 m)
Number of subjects: 9
Study 34959923 — intervention group
Group type: EXPERIMENTAL
Intervention: AP collagen peptides (APCPs) 1000 mg
Number of subjects: 50
Study 35152416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 47
Study 35152416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 35152416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (1-year follow-up)
Number of subjects: 47
Study 35152416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1-year follow-up)
Number of subjects: 47
Study 33616185 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) home intervention
Number of subjects: 223
Study 33616185 — intervention group
Group type: COMPARATOR
Intervention: Certified asthma educator (AE-C) services
Number of subjects: 223
Study 33616185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CHW and AE-C)
Number of subjects: 223
Study 32380427 — intervention group
Group type: EXPERIMENTAL
Intervention: Early relapse (ER) group
Number of subjects: 163
Study 32380427 — intervention group
Group type: COMPARATOR
Intervention: Progressive disease (PD) group
Number of subjects: 163
Study 35167133 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-glycerol cream (UGC)
Number of subjects: 49
Study 35167133 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol cream (GC)
Number of subjects: 49
Study 35167133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin cream (PC)
Number of subjects: 49
Study 35167133 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (NTC)
Number of subjects: 49
Study 34271702 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority rule dynamics with ε≥ε_{c}=1/9
Number of subjects: 0
Study 34271702 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority rule dynamics with ε<ε_{c}
Number of subjects: 0
Study 32330237 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (BF)
Number of subjects: 16
Study 32330237 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula (SF)
Number of subjects: 16
Study 32330237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based milk formula (MF)
Number of subjects: 16
Study 35490196 — intervention group
Group type: EXPERIMENTAL
Intervention: UCMV (umbilical cord milking with ventilation)
Number of subjects: 23
Study 35490196 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCV (delayed cord clamping with ventilation)
Number of subjects: 23
Study 35490196 — intervention group
Group type: EXPERIMENTAL
Intervention: UCM (umbilical cord milking without ventilation)
Number of subjects: 23
Study 32092479 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab therapy for 10 years
Number of subjects: 0
Study 33887775 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffalo Concussion Treadmill Test (BCTT)
Number of subjects: 20
Study 33887775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling test of exertion
Number of subjects: 20
Study 33887775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 20
Study 35443784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 50 mg b.i.d.
Number of subjects: 12
Study 34491650 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (at Xin (CO15), Gan (CO12), Shenmen (TF4), Pizhixia (AT4), Neifenmi (CO18)), once every 3 days for 4 weeks
Number of subjects: 72
Study 34491650 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage reduction method (sertraline hydrochloride reduced by 25% every week)
Number of subjects: 72
Study 34491650 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 72
Study 34491650 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage reduction method
Number of subjects: 72
Study 33414090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based diabetes screening interventions
Number of subjects: 339
Study 33414090 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performing pharmacists
Number of subjects: 339
Study 33414090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-performing pharmacists
Number of subjects: 339
Study 32105971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient infotainment system (study group)
Number of subjects: 86
Study 32105971 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study 33009351 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% velocity decrease (G10)
Number of subjects: 17
Study 33009351 — intervention group
Group type: COMPARATOR
Intervention: 20% velocity decrease (G20)
Number of subjects: 17
Study 33009351 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 17
Study 33421964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling Exercise Training (CET) combined with General Rehabilitation (GR) for 12 weeks, n = 20
Number of subjects: 40
Study 33421964 — intervention group
Group type: COMPARATOR
Intervention: General Rehabilitation (GR) alone for 12 weeks, n = 20
Number of subjects: 40
Study 37179020 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 513
Study 37179020 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 513
Study 34390083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-levofloxacin (TL) quadruple therapy (tetracycline 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Number of subjects: 108
Study 34390083 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-levofloxacin (AL) quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Number of subjects: 108
Study 34390083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-levofloxacin (TL) quadruple therapy
Number of subjects: 108
Study 34390083 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-levofloxacin (AL) quadruple therapy
Number of subjects: 108
Study 32567223 — intervention group
Group type: EXPERIMENTAL
Intervention: AE/CMA+ group
Number of subjects: 161
Study 32567223 — intervention group
Group type: COMPARATOR
Intervention: AE/CMA− group
Number of subjects: 161
Study 32567223 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 161
Study 35314457 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR1 slope in AASK
Number of subjects: 1172
Study 35314457 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR2 slope in AASK
Number of subjects: 1172
Study 35314457 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR1 in VA NEPHRON-D
Number of subjects: 1172
Study 35314457 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR2 in VA NEPHRON-D
Number of subjects: 1172
Study 33393112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg every 4 weeks (LAN)
Number of subjects: 198
Study 33393112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 32422066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 278
Study 32422066 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 278
Study 34104096 — intervention group
Group type: EXPERIMENTAL
Intervention: Planox® lemon verbena extract (LVE) 400 mg/human/day
Number of subjects: 60
Study 34104096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/human/day)
Number of subjects: 60
Study 36178686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with diabetes
Number of subjects: 383
Study 36178686 — intervention group
Group type: COMPARATOR
Intervention: Patient with opioid use disorder
Number of subjects: 383
Study 36178686 — intervention group
Group type: COMPARATOR
Intervention: Physicians with more than 20 years in practice (for opioid use disorder)
Number of subjects: 383
Study 36178686 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with more than 20 years in practice (for diabetes)
Number of subjects: 383
Study 36178686 — intervention group
Group type: COMPARATOR
Intervention: Women physicians (for opioid use disorder)
Number of subjects: 383
Study 36178686 — intervention group
Group type: EXPERIMENTAL
Intervention: Women physicians (for diabetes)
Number of subjects: 383
Study 33789735 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable multifocal contact lenses with + 0.50D addition
Number of subjects: 100
Study 33789735 — intervention group
Group type: COMPARATOR
Intervention: Daily disposable soft contact lenses (SCLs)
Number of subjects: 100
Study 32756488 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaded white leaf tea (SWLT)
Number of subjects: 0
Study 32756488 — intervention group
Group type: COMPARATOR
Intervention: Placebo green tea
Number of subjects: 0
Study 36104613 — intervention group
Group type: EXPERIMENTAL
Intervention: DFV890 + standard-of-care (SoC)
Number of subjects: 143
Study 36104613 — intervention group
Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 143
Study 33540464 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) in patients with AECOPD
Number of subjects: 44
Study 33540464 — intervention group
Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI) in patients without AECOPD
Number of subjects: 44
Study 33540464 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off point for CCI
Number of subjects: 44
Study 33540464 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off point for CIRS
Number of subjects: 44
Study 34821020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag (2.5, 3.75, 5, or 7.5 mg once daily) during Stage 4
Number of subjects: 339
Study 34821020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag during Stage 3
Number of subjects: 339
Study 34821020 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in the hetrombopag group
Number of subjects: 339
Study 34684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 31
Study 34684151 — intervention group
Group type: COMPARATOR
Intervention: Manual Infusion (MI)
Number of subjects: 31
Study 32912260 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (rewards to child contingent on both child's and parent's physical activity)
Number of subjects: 316
Study 32912260 — intervention group
Group type: COMPARATOR
Intervention: Child-based intervention (rewards to child contingent on child's physical activity)
Number of subjects: 316
Study 32912260 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention
Number of subjects: 316
Study 32912260 — intervention group
Group type: COMPARATOR
Intervention: Child-based intervention
Number of subjects: 316
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy (300 mg tablets, BID)
Number of subjects: 160
Study 35177277 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT)
Number of subjects: 160
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy
Number of subjects: 160
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in PSOC
Number of subjects: 160
Study 35177277 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in PSOC
Number of subjects: 160
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in PROC
Number of subjects: 160
Study 35177277 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in PROC
Number of subjects: 160
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in heavily pretreated PROC (>4 prior lines)
Number of subjects: 160
Study 35177277 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in heavily pretreated PROC (>4 prior lines)
Number of subjects: 160
Study 35177277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in BRCA-mutated PROC
Number of subjects: 160
Study 35177277 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in BRCA-wildtype PROC
Number of subjects: 160
Study 32768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 415
Study 32768376 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 415
Study 32768376 — intervention group
Group type: COMPARATOR
Intervention: Combined Training (AT+RT)
Number of subjects: 415
Study 32768376 — intervention group
Group type: COMPARATOR
Intervention: Control (lectures about health promotion)
Number of subjects: 415
Study 33832406 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole at a dose of up to 20 mg daily
Number of subjects: 90
Study 33832406 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine at a dose of up to 600 mg daily
Number of subjects: 90
Study 33832406 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol at a dose of up to 30 mg daily
Number of subjects: 90
Study 32074243 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurohormonal antagonists
Number of subjects: 0
Study 32074243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization and mitral valve repair
Number of subjects: 0
Study 32074243 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter mitral valve repair
Number of subjects: 0
Study 34331536 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (prevalent users)
Number of subjects: 5580
Study 34331536 — intervention group
Group type: COMPARATOR
Intervention: Statin initiators (new users)
Number of subjects: 5580
Study 34324783 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids administered to PWH (33.3%)
Number of subjects: 126
Study 34324783 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients (PWH)
Number of subjects: 126
Study 34324783 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative patients (non-PWH)
Number of subjects: 126
Study 34324783 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of mortality
Number of subjects: 126
Study 32977459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-CBT
Number of subjects: 100
Study 32977459 — intervention group
Group type: COMPARATOR
Intervention: Standard bariatric post-operative care
Number of subjects: 100
Study 35271566 — intervention group
Group type: EXPERIMENTAL
Intervention: Role uncertainty
Number of subjects: 0
Study 35271566 — intervention group
Group type: COMPARATOR
Intervention: State empathy induction
Number of subjects: 0
Study 35271566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait empathy (affective empathy)
Number of subjects: 0
Study 35271566 — intervention group
Group type: EXPERIMENTAL
Intervention: Role awareness
Number of subjects: 0
Study 36253804 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 80
Study 36253804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33645135 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenxiong Injection combined with conventional treatment
Number of subjects: 6197
Study 33645135 — intervention group
Group type: EXPERIMENTAL
Intervention: Honghua Injection combined with conventional treatment
Number of subjects: 6197
Study 33645135 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection combined with conventional treatment
Number of subjects: 6197
Study 33645135 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkang Injection combined with conventional treatment
Number of subjects: 6197
Study 35077558 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Gamification Group (SGG)
Number of subjects: 70
Study 35077558 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Based Gamification Group (TGG)
Number of subjects: 70
Study 35077558 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 70
Study 33627275 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - 9 sessions of intervallic exposure to heat (100 ± 2 °C) over 3 weeks
Number of subjects: 40
Study 33627275 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 40
Study 32567996 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous verbal rehabilitation training under inclusive education
Number of subjects: 60
Study 32567996 — intervention group
Group type: COMPARATOR
Intervention: No continuous verbal rehabilitation training
Number of subjects: 60
Study 33548748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation of Plantago major standardized by HPLC (1.88 mg/100g of quercetin)
Number of subjects: 130
Study 33548748 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study 32989062 — intervention group
Group type: COMPARATOR
Intervention: Standard practice support (practice facilitation, practice assessment with feedback, health information technology assistance, and collaborative learning sessions)
Number of subjects: 211
Study 32989062 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard support plus patient engagement support
Number of subjects: 211
Study 32989062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms of the intervention
Number of subjects: 211
Study 32989062 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention practices
Number of subjects: 211